Judicial Panel Coordinates Neurontin Sales Actions in Mass. District

WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation has consolidated 27 class actions and nine other lawsuits alleging wrongdoing by Pfizer Inc. subsidiaries in the marketing of Neurontin anti-seizure medication. In re Neurontin Marketing and Sales Practices Litigation, MDL No. 1629 (D. Mass.).

Plaintiffs in each case allege that Pfizer illegally promoted Neurontin for off-label uses.

Pfizer said May 13 it would set aside $430 million dollars to settle federal and state charges that its Warner-Lambert subsidiary engaged in extensive marketing of Neurontin for off-label uses despite little research into efficacy or safety.

Attorneys general from all 50 …